Boehringer Ingelheim boosts R&D commitment, promises up to 15 new product launches by 2025
Coming off a strong year of growth for its Eli Lilly-partnered SGLT2 inhibitor Jardiance, Boehringer Ingelheim is putting those gains right back into R&D — and setting some lofty goals for the next few years.
The German company spent nearly $4.5 billion (20% of net sales) on R&D last year, putting it just behind some of the pharma industry’s top spenders. And over the next five years, it plans on sinking more than $27 billion into drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
